Desloratadine in Patients With Ulcerative Colitis
Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis
Tanta University
44 participants
Jan 26, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.
mesalamine 1000 mg three times daily for 3 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07333716